The weaknesses are not so much the methodology but its application to the question which concerns the impact of a particular electronic discharge tool in a particular setting. This question has been tested in a RCT but unfortunately the results have not yet been published. The sample size for the RCT was based on a reduction of 25% in readmission or death with electronic discharge. My view on this is that this is a somewhat large reduction to expect from a simple intervention in heterogeneous patients in a complex setting. There was little difference between the arms and the study was not powered to show a more realistic difference.
It is therefore not surprising that the economic analysis showed considerable uncertainty around the incremental effectiveness of the intervention. The base case was $239,933 per QALY gained. While the economic analysis is fairly well described and reported, the question arises as to whether it was plausible to expect QALY gains from such an intervention, and whether a cost utility analysis should have been the focus of the paper (the protocol gives this as a secondary outcome and cost per death and cost per admission as primary outcomes -this should be addressed or explained in the paper). The main finding in practice was that it was cheaper to produce discharge summaries electronically than through standard practice. The findings are therefore of limited interest. The authors also acknowledge that contamination was likely to be a problem as clinicians were exposed to both interventions and may have improved the quality of the standard discharge summary while the trial was in progress.
The study is likely to have limited generalisability as, as the authors acknowledge, the impact of a specific edischarge summary will depend upon the context, including the level of IT innovation and quality of existing discharge procedures. The CHEERs checklist should have been included.
There was ethical approval for the trial but this could helpfully be noted in this paper as well as in the published protocol.
I suggest that the paper could be revised to reflect these comments, but ideally publication would follow or be simultaneous with the RCT results.
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GENERAL COMMENTS
Living and working in the UK I am not familiar with the Canadian healthcare system so I would suggest that someone familiar the Canadian healthcare system also reviewers the paper. Economic analysis is not my area of expertise and so I would suggest that specialist statistician review should also be employed. This is an interesting and well-designed study assessing the economic and clinical impact of a new electronic discharge transfer of care system. The aims and objectives were clearly stated and posed an interesting and relevant research question.
Main points
1. From the first read of the paper I had many questions regarding the method, all answered in the accompanying paper. However, the two papers need to be read in conjunction as the methodology in the review paper is too sparse to stand alone. It should be made clear to readers that the full methodology is described in the second paper and the publication should be in a manner to allow the two papers to be read together or the methodology of this paper needs to be expanded.
2. The study's outcomes included death and re-admission within 90 days. It did not measure or report whether these were avoidable or unavoidable events. This would have critical relevance to the results of this study because only avoidable deaths or re-admissions could be expected to be influenced by the intervention mechanism. This should be included as a study limitation.
Other comments:
Background P1 The background study referenced in the background section is the also the current study this paper is describing. The results and conclusion of the study are revealed in the opening section which is not the usual format for reporting. Method P 2 Line 30-32 it is not clear in the abstract what treatment the control group received P 5 Lines 22-24 it's not clear if the patient and user satisfaction was assessed during this study or if you are referring to results of another study. Results of another study may not extrapolate to this study e.g. if the electronic discharge platforms may have greatly different functions and usabilitys CONSORT checklist not provided Results P 10 Line 15 I wasn't clear here if the cost per patient was calculated from the number of patients seen in the study or the number of patients treated at the hospital within the study period. If it was calculated from the number seen within the study, then surely the electronic discharge transfer of care tool would be used on more patients in practice than those within the study and so the actual cost per patient would be far less? P 11 Line 6 my understanding is that the index hospitalisation is the cost of the initial admission and therefore not influenced by the intervention. If it is higher in the control group than the intervention group does this suggest that perhaps those patients are more unwell? This could have an influence on the outcome of the study P 11 It is not reported if the results are statistically different P 11 Line 31 the reporting is not clear it suggests a reduction in cost using the e DCT but there were more readmissions in this group so surely it was an increase in cost P 14 Line 28 agree other measures such as post-discharge adverse events or prescribing discrepancies could also be measured
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1. This is a well written paper which, given the question laid out in the protocol provided, uses appropriate methods.
It is therefore not surprising that the economic analysis showed considerable uncertainty around the incremental effectiveness of the intervention. The base case was $239,933 per QALY gained. While the economic analysis is fairly well described and reported, the question arises as to whether it was plausible to expect QALY gains from such an intervention, and whether a cost utility analysis should have been the focus of the paper (the protocol gives this as a secondary outcome and cost per death and cost per admission as primary outcomes -this should be addressed or explained in the paper). The main finding in practice was that it was cheaper to produce discharge summaries electronically than through standard practice. The findings are therefore of limited interest.
Response: Thank you for your thorough review of our paper. You bring up excellent points regarding the results and generalizability of the RCT. Of note, the RCT has now been published in BMJ Quality and Safety. While the 25% reduction in the composite endpoint may seem high, we grounded this difference in the literature. Based on other work, we did expect that 25% would be a meaningful difference. As with many neutral trials, we are disappointed with the lack of effect. However, complete reporting of all trial outcomes remains a necessary commitment from our perspective. Thus, we feel this manuscript represents an important addition to the literature irrespective of the neutral findings. Lastly, we have added sentences to Page 6 -Paragraph 2 to clarify the primary outcome.
2. The authors also acknowledge that contamination was likely to be a problem as clinicians were exposed to both interventions and may have improved the quality of the standard discharge summary while the trial was in progress.
Response: As the reviewer notes, we have identified contamination as one limitation of the RCT. This would have under-estimated the effectiveness within the RCT overall. In turn, this would have led to over-inflation of the cost per QALY estimate as the effect size is underestimated. We have included a discussion on this limitation on Page 16.
3. The study is likely to have limited generalisability as, as the authors acknowledge, the impact of a specific edischarge summary will depend upon the context, including the level of IT innovation and quality of existing discharge procedures.
Response: Our findings are indeed context specific. In an attempt to make our findings more generalizable, we have reported our costs in a disaggregated format to allow decision makers in other contexts to adapt our findings to their healthcare system. In addition, we feel that the pointed discussion of how existing IT infrastructure effects the economic value and thus the decision to adopt eDCT is a necessary contribution to the literature. On page 14/15, we have a rich policy discussion that highlights the need to consider multiple outcomes, objectives and current state of the healthcare system when considering eDCT adoption.
4. The CHEERs checklist should have been included.
Response: Thank you, the CHEERS checklist has now been included.
5. There was ethical approval for the trial but this could helpfully be noted in this paper as well as in the published protocol.
Response: A sentence has been added to Page 6 -Paragraph 1 to clarify the ethics approval.
6. I suggest that the paper could be revised to reflect these comments, but ideally publication would follow or be simultaneous with the RCT results.
Response: The RCT has now been published and the reference has been updated in the manuscript. A copy of the paper can be found at: http://qualitysafety.bmj.com/content/early/2017/08/18/bmjqs-2017-006635
